SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as community optimism grows around QNX's deepening integration into next-generation software-defined vehicles with key design wins like BMW's Neue Klasse and partnerships such as Alloy Kore with Vector, leading to expectations of accelerated revenue growth and strong Q3 earnings from its expanding automotive software portfolio.

Synthetix is a decentralized perpetual futures protocol built on Ethereum Mainnet. Synthetix uses a hybrid design — off-chain order matching on a high-performance CLOB with on-chain settlement — to deliver low latency, deep liquidity, and MEV-resistant execution while keeping custody and finality on Ethereum. Traders get CEX-like performance with on-chain security and composability. The protocol’s liquidity is provided by the Synthetix Liquidity Provider (SLP) vault and backstopped by staked SNX collateral, which underwrites the issuance of the sUSD stablecoin and the solvency of the SLP vault.

Synthetix Network 

Synthetix Network is trending due to the launch of its V3 perpetuals on Ethereum Mainnet, alongside a widely discussed $1 million trading competition and a strategic shift to a deflationary token model with upcoming buybacks. The community is buzzing with both bullish excitement for this return to L1 derivatives infrastructure and caution regarding market volatility.

Berachain

Berachain (BERA) is trending amid recent network upgrades like Bectra, new Proof-of-Liquidity reward vault approvals, and a notable crypto treasury initiative with Greenlane Holdings. The community is sharply divided, with bulls highlighting its growing TVL and unique PoL model for potential gains, while bears voice concerns over recent token unlocks and selling pressure.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is trending following the FDA's approval of BYSANTI (milsaperidone) for Bipolar I Disorder and Schizophrenia, with market participants eagerly anticipating a significant re-rating of its valuation. The drug's New Chemical Entity (NCE) status and patent protection through 2044, combined with the potential of its GLP-1 nausea candidate, are fueling widespread community discussion about a possible near-term buyout.

Insight Enterprises, Inc. engages in the provision of information technology (IT) hardware, software, and services. The firm offers supply chain optimization, connected workforce, cloud and data center transformation, and digital innovation. It operates through the following geographical segments: North America, Europe, Middle East, and Africa (EMEA), and Asia-Pacific (APAC). The company was founded by Eric J. Crown and Timothy A. Crown in 1988 and is headquartered in Chandler, AZ.

Insight Enterprises Inc.

Insight Enterprises is trending following its Q4 earnings recap, which revealed strong GAAP EPS growth and a positive outlook, complemented by strategic moves like a new AWS collaboration and the Sekuro cybersecurity acquisition. The community remains divided, discussing the company's strong positioning in digital transformation and cloud against some revenue misses, fueling active debate and technical plays including short squeeze speculation.

BlackRock Institutional Trust Company N.A. - iShares Core S&P Mid-Cap ETF

iShares Core S&P Mid-Cap ETF

The iShares Core S&P Mid-Cap ETF is trending due to community discussions around its recent stock split and overall strong performance, with upcoming forced buying from UiPath's inclusion in the S&P MidCap 400 further fueling enthusiasm for mid-cap exposure and a potential market rotation.

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Celldex Therapeutics Inc.

Celldex Therapeutics is trending following recent positive Phase 2 data for its lead asset barzolvolimab in chronic urticaria, which showcases strong efficacy and high complete response rates and has led to bullish analyst price targets. However, the community is debating whether mechanism-related side effects and long approval timelines will temper its 'blockbuster' potential, contributing to recent share price volatility.

Krystal Biotech, Inc. operates as a biotechnology company, which engages in developing and commercializing pharmaceutical products. It offers the product, VYJUVEK. The company was founded by Krish S. Krishnan and Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

Krystal Biotech Inc

Krystal Biotech is gaining traction following solid Vyjuvek sales and encouraging pipeline updates for gene therapies in cystic fibrosis and ocular conditions, fueling community optimism about its commercial execution and potential as a buyout target within the consolidating biotech sector.

Thermo Fisher Scientific Inc. serves the scientific community through a broad offering of innovative products and services. Thermo Fisher Scientific serves customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial, research and development, quality and process control settings. The company’s global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through its brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. The company continuously increases its depth of capabilities across its broad portfolio of innovative products and services and leverages its extensive global channels to address customers’ needs. The company does this through organic investments in research and development, capacity and capabilities and through acquisitions. The company’s goal is to enable its customers to be more productive in an increasingly competitive business environment, enable them to accelerate innovation, solve their challenges and advance their important work. The company’s history roots back to the year 1956 when the business was first established. Thermo Fisher Scientific was formed in 2006 from the merger of Thermo Electron and Fisher Scientific and is headquartered in Waltham, MA.

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific is trending as the market digests its recent Q4 earnings beat, which highlighted solid sales growth and operational execution amidst some lingering margin pressures. The community is also actively discussing strategic moves, including a significant acquisition and a new R&D partnership for cancer screening, alongside a substantial share repurchase authorization signaling confidence in future growth.

CSX Corp. engages in the provision of rail-based freight transportation services. Its services include rail service, the transport of intermodal containers and trailers, rail-to-truck transfers and bulk commodity operations. It operates through Rail and Trucking segments. The Rail segment provides rail-based transportation services including traditional rail service and the transport of intermodal containers. The Trucking segment consists of Quality Carriers. The company was founded in 1827 and is headquartered in Jacksonville, FL.

CSX Corp.

CSX is trending due to heightened speculation around potential strategic options, including a merger or takeover, amplified by reports that the company is engaging with Goldman Sachs to explore opportunities. This buzz comes amid significant consolidation within the rail industry and a recent leadership change, with the community also noting the company's large fleet modernization investment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Buying: Hyperion DeFi (NASDAQ:HYPD) CFO Acquires 27,950 Shares of Stock

Hyperion DeFi, Inc. (NASDAQ:HYPD - Get Free Report) CFO David Knox purchased 27,950 shares of the business's stock in a transaction that occurred on Wednesday, December 31st. The stock was bought at...

Hyperion DeFi Names Hyunsu Jung CEO

(RTTNews) - Hyperion DeFi, Inc. (HYPD), an ophthalmic technology company, on Monday announced that its Board has appointed Hyunsu Jung as Chief Executive Officer, effective immediately...

This Hyperion DeFi Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Wednesday

Michael Geltzeiler Buys 30,000 Shares of Hyperion DeFi (NASDAQ:HYPD) Stock

Hyperion DeFi, Inc. (NASDAQ:HYPD - Get Free Report) Director Michael Geltzeiler acquired 30,000 shares of the business's stock in a transaction on Wednesday, December 17th. The shares were purchased...

Crypto Treasuries Create SPAC Boom  Bloomberg Crypto 11/25/2025

'Bloomberg Crypto' covers the people, transactions, and technology shaping the world of decentralized finance. Today's guests: Dynamix CEO Andrejka Bernatova, Hyperion DeFi CEO Hyunsu Jung and...

Kevin Hassett Frontrunner for Fed Chair, SPACS Latched to Crypto DATS  Bloomberg Crypto 11/25/2025

'Bloomberg Crypto' covers the people, transactions, and technology shaping the world of decentralized finance. Today's guests: PIMCO Economist Tiffany Wilding, Dynamix CEO Andrejka Bernatova and...

Shares of Hyperion DeFi (HYPD) rose by more than 21% in afternoon trading on Tuesday as investors cheered the company’s leadership changes.&nbsp;The management said that CEO Michael Rowe had notified them of his intent to resign. In the interim, Chief Investment Officer and board member Hyunsu Jung will step in as acting chief executive. He will be supported by the company’s newly appointed CFO, Happy Walters, who is also joining the board, as well as strategic advisor Max Fiege.One retail trader forecast that Jung replacing Rowe should lead to a “strong month” for&nbsp;<a href="http://stocktwits.com/symbol/HYPD">Hyperion’s stock.</a><stembedurl>https://stocktwits.com/gnargnarinthepewpew/message/627942727</stembedurl>Another retail trader argued the leadership change signaled a pivot toward the company’s treasury activities. The company announced in August its plan to pivot to a digital asset treasury (DAT) backed by Hyperliquid (HYPE) tokens, becoming the first publicly traded company to do so.&nbsp;The user also forecast that the company may sell its non-core assets later this year and use those funds to buy more HYPE tokens. They said the shift could justify a valuation double the current level, with the stock potentially climbing above $20 next quarter if HYPE continues to gain momentum.<stembedurl>https://stocktwits.com/YorkMeister/message/627943505</stembedurl><a href="https://stocktwits.com/symbol/HYPE.X">HYPE token’s price</a> gained 4.2% in the last 24 hours despite weakness in the broader cryptocurrency market. Retail sentiment around the token moved higher within ‘bullish’ territory over the past day, with chatter increasing to ‘high’ from ‘normal’ levels.Meanwhile, the overall retail sentiment around Hyperion’s stock improved but remained in ‘bearish’ territory over the past day.&nbsp;<figure class="image"><img style="aspect-ratio:793/91;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_09_142833_png_4cac417a0f.webp" alt="Screenshot 2025-09-09 142833.png" width="793" height="91"><figcaption>HYPD retail sentiment and message volume on April 9 as of 2:30 p.m. ET | Source: Stocktwits</figcaption></figure>The stock has declined by more than 30% this year and has fallen by 80% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/qmmm-soars-over-300-after-unveiling-100-m-crypto-treasury-plan/chwK96mRdtY">QMMM Soars Over 300% After Unveiling $100M Crypto Treasury Plan – Here Are The Tokens It’s Backing</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of stock price rising. (Source: Yuichiro Chino/Getty Images)

Hyperion DeFi Stock Jumps As Retail Traders Back CEO Shake-Up 

The company announced on Tuesday that CEO Michael Rowe will be stepping down, with Chief Investment Officer Hyunsu Jung taking over as acting chief executive.

Equity

Hyperion DeFi, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in Laguna Hills, CA.

HYPD
Hyperion DeFi Inc.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest HYPD News

HYPDHyperion DeFi Inc.